Personalised medicine is transforming healthcare by tailoring treatments to specific patient populations, often based on genetic or other biomarker features. But while the science is moving fast, the patent landscape presents ongoing challenges.

At HGF, we advise clients on securing protection for personalised therapies, companion diagnostics, and patient stratification methods. Key issues in this space include differing approaches to diagnostic claims and novelty, particularly the concept of inherency in US law, compared to EPO standards. These differences are crucial when claiming treatments of newly identifiable patient groups who may have previously received a treatment without a formal diagnosis.

Our team has significant in-house experience in both small and large molecule drug development, particularly in oncology. We also understand the complexities of collaboration between pharma companies and diagnostic partners, and the contractual and IP issues these arrangements raise.

Whether advising on freedom-to-operate, licensing, or securing robust protection for personalised medicine, HGF brings legal expertise, sector insight, and commercial awareness to help clients in this evolving field.